Sensei Biotherapeutics Reports $16.4 Million Net Loss, Announces Workforce Reduction and Strategic Review

Sensei Biotherapeutics, Inc. reported a net loss of $16.4 million for the nine months ended September 30, 2025, a decrease from a net loss of $22.4 million during the same period in 2024. The company's total operating expenses for the nine months were $17.3 million, down from $24.3 million in the prior year, reflecting a significant reduction in both research and development (R&D) and general and administrative (G&A) expenses. R&D expenses decreased to $8.8 million from $14.1 million, while G&A expenses fell to $8.5 million from $10.2 million. The decrease in expenses is attributed to lower personnel costs, reduced clinical trial expenses, and decreased costs associated with facilities and equipment.

In terms of financial position, Sensei's total assets decreased to $27.6 million as of September 30, 2025, down from $45.4 million at the end of 2024. The decline in assets was primarily due to a reduction in marketable securities, which fell to $14.5 million from $31.3 million. The company's cash and cash equivalents increased slightly to $10.6 million from $10.0 million, indicating a modest improvement in liquidity. However, the accumulated deficit grew to $278.4 million, reflecting ongoing operational losses.

Strategically, Sensei Biotherapeutics announced the discontinuation of its lead product candidate, solnerstotug, and initiated a comprehensive review of strategic alternatives aimed at maximizing shareholder value. This review may include options such as asset sales, licensing arrangements, or a potential merger. As part of this strategic shift, the company plans to implement a workforce reduction of approximately 65%, which is expected to incur cash expenditures of around $1.6 million primarily for severance payments. The remaining employees will focus on exploring strategic alternatives and managing compliance with regulatory requirements.

Operationally, Sensei's workforce reduction and the discontinuation of solnerstotug are significant changes that reflect the company's shift in focus. The company has not generated any revenue from product sales and does not expect to do so in the near future. As of September 30, 2025, Sensei had approximately 1,261,290 shares outstanding following a 1-for-20 reverse stock split that took effect on June 16, 2025. The company continues to face challenges typical of early-stage biotechnology firms, including the need for additional capital to fund operations and the uncertainty surrounding the successful development of its product candidates.

Looking ahead, Sensei Biotherapeutics has expressed substantial doubt about its ability to continue as a going concern beyond one year from the issuance of its financial statements. The company anticipates ongoing operating losses and negative cash flows, which may necessitate further strategic actions to ensure financial stability. The outcome of the strategic review process remains uncertain, and there is no guarantee that any potential transaction will be completed or that it will enhance shareholder value.